We provide a breakthrough in transplant treatment
Our focus is on discovery and early clinical development of treatments for well-defined patient populations suggesting relevant commercial opportunities. We aim to retain ownership of product candidates through to proof of concept after which we expect to partner with established pharma companies for late-stage development and commercialisation.
US28 is a novel CMV-specific target
INNOVATION IN TARGETING CMV VIRUS
Leveraging the active function of US28 to gain access to CMV infected cells
- Membrane protein encoded by the virus
- Exclusively expressed on virus infected cells
- Expressed during both lytic and latent phase
- Continuously internalizing
- Acts as a chemokine scavenger
Our patented SYN002 drug candidate
SAFE AND TARGETED
SELECTIVELY kills infected cells, without impacting organ function
SYN002 effectively kills CMV infected cells, eliminating infection
Uniquely Targets BOTH Latent and Lytic Infected Cells
Strong foundational
and translational science
Risk factors for CMV infection in transplantation
Latent viral load is key driver of CMV reactivation
The latent CMV reservoir facilitates CMV disease
Reduction of the latent CMV load significantly reduces risk of CMV disease
The latent virus load is the key parameter that determines risks of CMV Disease during immuno-suppression1
High latent virus load →
63%
CMV reactivation
Reddehase JEM. 1994
Low latent virus load →
7%
CMV reactivation
Lowering the latent virus in mice strongly affects the incidence of CMV recurrence2
5-fold reduction
lowers recurrence by
60%
Steffens, JV1998
Clear correlation between latent viral load and reactivation & active productive infection (1) Reddehase JEM. 1994 and 2) Steffens, JV1998).